Skip to main content
. Author manuscript; available in PMC: 2013 Jul 26.
Published in final edited form as: N Engl J Med. 2012 Jan 19;366(3):207–215. doi: 10.1056/NEJMoa1105358

Figure 2. Examples of the Mutation and MAPK-Signaling Analysis in Cutaneous Squamous-Cell Carcinomas or Keratoacanthomas.

Figure 2

Immunohistochemical staining for pERK (brown) of samples of normal adjacent skin (left) and of cutaneous squamous-cell carcinomas (right) is shown from two patients in the validation set who were treated with vemurafenib. In these patients, both of whom had KRAS G12 mutations, the lesions were diagnosed as well-differentiated squamous-cell carcinomas that appeared 87 days (Panel A) and 51 days (Panel B) after vemurafenib therapy was begun.